Abstract
Background Previous studies show an association between smoking and anal cancer. The objective of this study was to assess the association between smoking and anal HPV prevalence in men.
Methods The HPV infection in Men (HIM) Study is a multinational study that enrolled HIV-negative men. At baseline anal specimens were collected from 1994 participants. HPV genotyping was assessed by Linear Array. Prevalence ratios (PR) were used to assess the association between smoking and anal HPV prevalence.
Results Current smokers have a higher prevalence of any anal HPV (adjusted PR (aPR)=1.36, 95%CI: 1.06-1.73) and LR-HPV (aPR=1.59, 95%CI: 1.20-2.12) compared to never smokers. There were no difference in the prevalence of anal HPV between former and never smokers.
Smoking status was not associated with the prevalence of anal HPV among men that have sex with men (MSM). Among men that have sex with women (MSW), current smokers had an increased prevalence for LR-HPV (aPR=1.60 95% CI: 1.02-2.50) compared to never smokers.
Conclusions While there was no difference in anal HPV prevalence among MSM by smoking status, MSW that currently smoked had a higher prevalence of LR-HPV. Futher research is needed to assess the role smoking in anal HPV persistence.
Competing Interest Statement
A.R.G., L.L.V., and E.L.P. are members of the Merck Advisory Board. S.L.S. (IISP53280) and A.G.N. (IISP33707) received grants from Merck Investigator Initiated Studies Program. No conflicts of interest were declared for any of the remaining authors.
Funding Statement
The HIM Study was supported by the National Cancer Institute [R03 AI127205 to S.L.S. and R01 CA098803 to A.R.G.] and National Institute of Allergy and Infectious Disease (R21 AI101417 to A.G.N.), National Institutes of Health; and the Merck Investigator Initiated Studies Program (IISP33707 to A.G.N.). Dr. Sudenga (K07 CA225404) is supported by the National Cancer Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent. Study protocols were approved by the Institutional Review Boards at the University of South Florida (Tampa, FL, US), the Ludwig Institute for Cancer Research, the Centro de Referencia e Treinamento em Doencas Sexualmente Transmissiveis e AIDS (Sao Paulo, Brazil), and the Instituto Nacional de Salud Publica (Cuernavaca, Mexico).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
